Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $194.49M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.22
• Revenue Growth: -99.87%
• EPS Growth: -5.45%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 292,161,650
• 10 Day Avg. Volume: 827,826
• 30 Day Avg. Volume: 1,173,601
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3019.57
• Price to Cash Flow (P/CF): -1.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.30
• Price Target Upside: 248.48% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

Lyell Immunopharma's overall stock score reflects substantial financial challenges, with an emphasis on the lack of revenue generation and persistent losses. While there is some technical momentum, the valuation metrics highlight significant difficulties, including a negative P/E ratio and no dividends. The company's solid balance sheet provides some stability, but the operational risks remain considerable.

Positive Factors

Clinical Data

Initial Phase 1/2 data of IMPT-314 in 2L+ LBCL to be presented at ASH.

Financial Performance

Lyell ended 3Q24 with $461M in cash, which management expects to provide an operational runway into 2027.

Negative Factors

Market Competition

Competing with established players Gilead, Bristol, and Novartis is likely to be challenging, especially given their sizeable infrastructure investments.

Market Limitation

The CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.

Strategic Uncertainty

The decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma (LYEL) is a biotechnology company focused on developing innovative cell therapies for cancer. The company leverages its expertise in T-cell biology and genetic engineering to create products aimed at enhancing the functionality and durability of T-cells, with the goal of improving outcomes for patients with solid tumors. Lyell operates within the biopharmaceutical sector, offering advanced therapeutic solutions designed to address unmet medical needs in oncology.

How the Company Makes Money

Lyell Immunopharma primarily generates revenue through collaboration agreements and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and potential royalties from product sales. As a pre-commercial stage company, Lyell does not yet have products on the market, so its earnings are largely dependent on external funding sources, including research grants and investments from venture capital firms. Additionally, Lyell may engage in licensing agreements that allow other companies to use its proprietary technologies, further contributing to its revenue streams.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma is experiencing severe financial challenges, with a significant decline in revenue and high operating losses, as evident from the income statement. Despite a stable balance sheet with low debt, negative cash flows indicate liquidity issues, raising concerns about long-term financial sustainability.

Income Statement

Lyell Immunopharma's income statement shows significant challenges. The company has faced a consistent decline in revenue over the years, with TTM revenue at $63,000 compared to $84,683,000 in 2022. Margins are extremely low, with a negative gross profit margin and a net profit margin deeply in the red at -323.8% TTM. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies and high operating losses.

Balance Sheet

The balance sheet indicates a moderate level of financial stability. The debt-to-equity ratio is relatively low at 0.10, suggesting a conservative use of leverage. However, the equity ratio has decreased over time, now standing at 85.7% TTM, which is still strong but shows a diminishing trend. The return on equity is negative, reflecting the company's unprofitable status.

Cash Flow

Cash flow statements reveal a concerning trend with negative operating and free cash flows, suggesting liquidity issues. The operating cash flow to net income ratio is 0.76, indicating operational inefficiencies. Free cash flow growth rate is negative, highlighting the company's struggles to generate positive cash flows.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
63.00K	130.00K	84.68M	10.65M	7.76M	657.00K
	Gross Profit
-14.92M	130.00K	68.22M	-3.88M	281.00K	657.00K
	EBIT
-219.77M	-247.01M	-183.12M	-214.78M	-211.94M	-102.09M
	EBITDA
-197.02M	-226.76M	-166.65M	-199.94M	-207.64M	-100.83M
	Net Income Common Stockholders
-203.99M	-234.63M	-4.75M	-285.50M	-198.53M	-121.26M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
436.05M	546.22M	640.15M	614.79M	612.62M	436.05M
	Total Assets
0.00	750.03M	937.56M	1.13B	908.28M	555.63M
	Total Debt
0.00	63.17M	67.70M	67.82M	54.57M	27.47M
	Net Debt
436.05M	-82.48M	-55.85M	-226.01M	-85.83M	-69.20M
	Total Liabilities
0.00	95.08M	104.31M	197.62M	189.84M	147.58M
	Stockholders Equity
408.06M	654.95M	833.25M	929.79M	718.44M	408.06M
Cash Flow		Free Cash Flow
-156.23M	-166.38M	-193.83M	-191.75M	-212.35M	23.43M
	Operating Cash Flow
-155.79M	-163.69M	-169.56M	-126.25M	-160.87M	39.47M
	Investing Cash Flow
-31.77M	184.05M	-11.54M	-121.57M	-273.52M	-422.43M
	Financing Cash Flow
1.65M	1.74M	10.63M	401.24M	476.79M	351.16M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.66
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Negative. The current price of 0.66 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.63, and below the 200-day MA of 1.24, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 49.59 is Neutral, neither overbought nor oversold. The STOCH value of 42.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
IOVA	48 Neutral	$1.28B	―	-57.48%	―	13698.99%	31.46%
CRSP	48 Neutral	$3.72B	―	-19.20%	―	-89.95%	-123.71%
LYEL	46 Neutral	$194.49M	―	-33.22%	―	-99.87%	-5.45%
ADAP	44 Neutral	$114.38M	―	-53.54%	―	145.37%	57.01%
BLUE	42 Neutral	$38.57M	―	-270.20%	―	144.50%	-141.91%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%

Lyell Immunopharma Corporate Events

Lyell Immunopharma’s Strategic Moves and Leadership Expansion

Lyell Immunopharma, a leader in next-generation CAR T-cell therapies, has acquired ImmPACT Bio to enhance its clinical pipeline with the promising IMPT-314 product candidate. This acquisition aims to accelerate the development of therapies for aggressive B-cell non-Hodgkin lymphoma, with pivotal trials expected to begin in 2025. Alongside this strategic move, Dr. Sumant Ramachandra joins Lyell’s Board of Directors, bringing valuable expertise to advance innovative cancer treatments. Lyell’s robust financial position is expected to support key clinical milestones through 2027.

Lyell Immunopharma Acquires ImmPACT Bio to Enhance Pipeline

Lyell Immunopharma is set to acquire ImmPACT Bio to bolster its pipeline with advanced CAR T-cell therapies, focusing on IMPT-314, a promising dual-targeting treatment for B-cell lymphoma. The acquisition aims to enhance Lyell’s clinical-stage offerings and drive innovation in cancer treatments. With the deal valued at $30 million in cash and shares, Lyell plans to prioritize next-generation therapies, discontinuing some existing programs to concentrate resources on the most differentiated candidates, with operations funded through 2027.